期刊
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
卷 930, 期 -, 页码 129-135出版社
ELSEVIER
DOI: 10.1016/j.jchromb.2013.05.003
关键词
Alzheimer's disease (AD); Biomarker; Cerebrospinal fluid (CSF); Targeted proteomics; Multiple reaction monitoring (MRM)
资金
- National Institutes of Health [R01MH59926, 2P20RR016472, 5P30RR031160]
- New York State Office of Science, Technology, and Academic Research
- Institute for the Study of Aging
There is significant interest in the development of methods to validate novel biomarkers for Alzheimer's disease (AD) diagnosis. Previously, a proteomic panel of cerebrospinal fluid (CSF) biomarker candidates that differentiated AD and non-AD CSF with accuracy higher than 90% was found; information about these CSF proteins can be used to develop multiple reaction monitoring (MRM) based analytical assays, which offer the possibility of quantifying protein expression level changes in samples, as well as, validation among multiple laboratories. Here we report an MRM assay that demonstrates good linearity (average R-2 = 0.969) and reproducibility (average coefficient of variance of 6.93%) for the proposed AD CSF biomarkers. MRM quantification results of A beta 1-40, A beta 1-42, retinol-binding protein and cystatin C correlated well with those from ELISA (average R-2 = 0.974). Analysis shows that 12 out of 16 selected targets exhibit the same trend in protein expression as that in literature. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据